Prophylactic Antifungal Treatment in Critically Ill COVID-19 Patients: Meta-Analysis

Overview

This systematic review and meta-analysis evaluated antifungal prophylaxis effectiveness in critically ill COVID-19 patients at risk for COVID-19-associated pulmonary aspergillosis (CAPA). Nine studies including 1,321 ICU patients showed that prophylactic antifungal treatment may reduce CAPA incidence and associated mortality, although evidence is limited by study heterogeneity and design.

Background

Critically ill COVID-19 patients with respiratory failure are at increased risk for invasive fungal infections such as CAPA, which has a prevalence of 10–33% and mortality exceeding 50% in ICU settings. While antifungal prophylaxis is well established in other immunocompromised populations, its role in COVID-19 remains controversial due to limited randomized controlled trials and heterogeneous study designs. The high mortality burden of CAPA underscores the need for effective preventive strategies. This meta-analysis aims to synthesize current evidence on antifungal prophylaxis efficacy in this population.

Data Highlights

Key Findings

• CAPA prevalence in critically ill COVID-19 patients ranges from 10% to 33%, with mortality rates exceeding 50% in ICU settings.
• Antifungal prophylaxis, particularly with triazole agents like posaconazole, shows promise in reducing CAPA incidence.
• The POSACOVID trial supports posaconazole prophylaxis in mechanically ventilated patients, but efficacy depends on baseline CAPA incidence.
• Most included studies were observational cohorts with heterogeneity in patient selection, prophylactic regimens, and outcome measures.
• Meta-analysis used random-effects models due to study heterogeneity and found a potential benefit of prophylaxis on CAPA incidence and mortality.
• Risk of bias was assessed using Cochrane and ROBINS-I tools, with sensitivity analyses performed to address heterogeneity.

Clinical Implications

Clinicians should consider antifungal prophylaxis in critically ill COVID-19 patients at high risk for CAPA, especially those requiring mechanical ventilation. However, decisions must balance potential benefits against risks of antifungal resistance and adverse effects. Given current evidence limitations, prophylaxis should be individualized and guided by local CAPA incidence and patient risk factors.

Conclusion

Antifungal prophylaxis may reduce CAPA incidence and mortality in critically ill COVID-19 patients, but further high-quality randomized trials are needed to establish definitive recommendations. Until then, prophylactic strategies should be carefully tailored to patient risk profiles and institutional epidemiology.

References

1. Xie et al. 2025 -- Prophylactic Antifungal Treatment in Critically Ill Patients with COVID-19: A Systematic Review and Meta-Analysis